Lyell Immunopharma (LYEL) FY2025 10-K Risk Factors: 8 New, 13 Dropped

What the changes say

Lyell is advancing cell therapy candidates like ronde-cel and LYL273 while managing clinical, manufacturing, and collaboration risks.

What changed since the prior 10-K

New

NewRisks Related to Our Business and Industry
and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to use and expand our technologies to develop any product candidate
Our product candidates like ronde-cel in the PiNACLE trial and LYL273 are unproven, and nonclinical data may not predict human safety or efficacy.
NewRisks Related to Our Business and Industry
under our arrangements may be adversely affected by business combinations or significant changes in our collaborator’s business strategy
Collaborator business combinations or IT compromises could harm our commercialization efforts, operations, and trigger litigation or fines.
NewRisks Related to Our Business and Industry
International trade policies, including tariffs, sanctions and trade barriers, may adversely affect our business, financial condition, results of operations and prospects
U.S. and foreign tariffs, trade barriers, and retaliatory measures could disrupt our international suppliers and biopharmaceutical operations.
NewRisks Related to Manufacturing
If our clinical manufacturing facility in Bothell, Washington or any of our potential contract manufacturing organizations is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected
Damage or disruption to our Bothell, Washington manufacturing facility or third-party facilities could halt production and be expensive to replace.
NewRisks Related to Our Dependence on Third Parties
In particular, failure by any collaborator to meet its obligations under our collaboration agreements or to apply sufficient efforts at developing and commercializing collaboration products may adversely affect our business, financial condition and our results of operations
Collaborators may fail to meet obligations or apply sufficient effort to develop and commercialize collaboration products.
NewRisks Related to Regulation and Legal Compliance
could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products
Post-approval regulatory requirements, cGMP compliance, and mandatory Phase 4 trials for our cell therapies could impose significant expenses.
NewRisks Related to Regulation and Legal Compliance
obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue
Securing coverage and adequate reimbursement from Medicare, Medicaid, and private insurers is essential, and our novel cell therapies require extra education.
NewRisks Related to Ownership of Our Common Stock
stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock
Our charter designates the Delaware Court of Chancery as the exclusive forum for substantially all stockholder disputes.

Dropped

DroppedRisks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital
our product candidates or delay, limit, reduce or terminate our establishment of sales, marketing and distribution capabilities or other activities that may be necessary to commercialize our product candidates
DroppedRisks Related to Our Business and Industry
we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations
DroppedRisks Related to Our Business and Industry
If we cannot maintain our company culture as we grow, our success and our business may be harmed
DroppedRisks Related to Manufacturing
require regulatory approval before selling any products manufactured at that facility. Such an event could substantially delay our clinical trials or commercialization of our product candidates
DroppedRisks Related to Our Dependence on Third Parties
We may not be able to successfully integrate ImmPACT into our business, including manufacturing of IMPT-314 at LyFE, or to realize the anticipated benefits of the acquisition
Milestone and success payment obligations may cause operating results to fluctuate.
DroppedRisks Related to Our Dependence on Third Parties
Additionally, general market and economic conditions or governmental actions generally may inhibit our successful integration of ImmPACT
DroppedRisks Related to Our Dependence on Third Parties
Failure to successfully address these and other issues related to the acquisition could have a material adverse effect on our financial condition and results of operations and could adversely affect our ability to successfully implement our business strategy
DroppedRisks Related to Regulation and Legal Compliance
sanctions prohibit the provision of certain products and services to countries, governments and persons targeted by U.S. sanctions
Novel technologies may not result in approvable or marketable products.
DroppedRisks Related to Regulation and Legal Compliance
Outside the United States, an increasing number of laws, regulations and industry standards may govern data privacy and security. For example, the EU GDPR and the UK GDPR impose strict requirements for processing personal data
DroppedRisks Relating to Our Intellectual Property
initiate, and even if we or our licensors are successful, the damages or other remedies awarded, if any, may not be commercially meaningful
Failure to maintain company culture during growth and prior workforce reductions.
DroppedRisks Relating to Our Intellectual Property
candidates and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities
DroppedRisks Related to Ownership of Our Common Stock
We may be unable to comply with the applicable continued listing requirements of The Nasdaq Global Select Market
DroppedRisks Related to Ownership of Our Common Stock
Indemnity provisions in various agreements potentially expose us to substantial liability for intellectual property infringement, data protection and other losses

Reworded

95% rewrittenRisks Related to Regulation and Legal Compliance
Changes in healthcare policies, laws and regulations may impact our ability to obtain approval for, or commercialize our product candidates, if approved
Updated references to the Affordable Care Act, removing explicit mention of the Health Care and Education Reconciliation Act.
85% rewrittenRisks Relating to Our Intellectual Property
We may be subject to claims that our employees, consultants or independent contractors have breached non-compete or non-solicit obligations
Added that litigation may be necessary to defend against employee non-compete claims, adding potential costs and management distraction.
Was: We may be subject to claims that our employees, consultants or independent contractors have breached non-compete or non-solicit obligations and/or wrongfully used or disclosed confidential information of third parties
82% rewrittenRisks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
Added the formal title 'Tax Cuts and Jobs Act of 2017' and specified U.S. code sections for ownership changes.
80% rewrittenRisks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital
We operate in a rapidly evolving field and have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability
Reordered and slightly refined operational descriptions regarding maintaining intellectual property portfolios.
69% rewrittenRisks Related to Ownership of Our Common Stock
Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock
Minor stylistic and phrasing cleanup with no substantive change to anti-takeover provisions.
67% rewrittenRisks Related to Regulation and Legal Compliance
Our cell therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in our ability to achieve regulatory approval, commercialization or payor coverage of our product candidates
Added specific mention of LYL273 in development for mCRC and institutional biosafety committee (IBC) review requirements for CAR T-cells.
Was: Our cellular therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in our inability to achieve regulatory approval, commercialization or payor coverage of our product candidates
65% rewrittenRisks Related to Regulation and Legal Compliance
The FDA and comparable foreign regulatory approval processes are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approvals of our product candidates, our business will be substantially harmed
Retained core clinical trial and FDA approval unpredictability risks with minor stylistic polish.
64% rewrittenRisks Related to Ownership of Our Common Stock
The requirements of being a public company require our management to devote substantial time to compliance initiatives and corporate governance practices and could divert management’s attention and strain our resources
Specified the exact date (October 2024) of the ImmPACT acquisition for public company compliance reporting.
58% rewrittenRisks Related to Our Business and Industry
We acquired ImmPACT in October 2024 and LYL273 in November 2025 and may not realize the benefits of such acquisitions or any potential future collaborations, licenses, product acquisitions or other strategic transactions
Was: We recently acquired ImmPACT and may not realize the benefits of such acquisition or any potential future collaborations, licenses, product acquisitions or other strategic transactions
57% rewrittenRisks Related to Manufacturing
Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all
57% rewrittenRisks Related to Regulation and Legal Compliance
Ronde-cel has received Fast Track and RMAT designations, and LYL273 has received Fast Track designation, from the FDA, but receipt of such designations or any other designation may not actually lead to a faster development, regulatory review or approval process, and does not assure ultimate FDA approval
Was: IMPT-314 has received Fast Track designation from the FDA, but receipt of such designation or any other designation, such as Regenerative Medicine Advanced Therapy designation, may not actually lead to a faster development, regulatory review or approval process, and does not assure ultimate FDA approval
53% rewrittenRisks Related to Regulation and Legal Compliance
We may be subject to applicable fraud and abuse, including anti-kickback and false claims, transparency, health information privacy and security and other healthcare laws. Failure to comply with such laws may result in substantial penalties
52% rewrittenRisks Related to Our Dependence on Third Parties
Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites
51% rewrittenRisks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital
We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts
51% rewrittenRisks Related to Ownership of Our Common Stock
Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or our products
50% rewrittenRisks Related to Ownership of Our Common Stock
Sales of a substantial number of shares of our common stock by our existing stockholders could cause the price of our common stock to decline
49% rewrittenRisks Related to Our Dependence on Third Parties
We have in the past, and we may in the future, form or seek collaborations or strategic alliances or enter into additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements
48% rewrittenRisks Related to Ownership of Our Common Stock
Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price
45% rewrittenRisks Related to Our Business and Industry
We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us
44% rewrittenRisks Relating to Our Intellectual Property
We may face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third party’s trade secrets, we may be prevented from further using these trade secrets, which could limit our ability to develop our product candidates
41% rewrittenRisks Related to Ownership of Our Common Stock
Changes in tax laws or regulations, including those that are applied adversely to us or our customers, may have a material adverse effect on our business, cash flow, financial condition, results of operations, effective tax rate or compliance costs
39% rewrittenRisks Related to Our Business and Industry
If we are unable to successfully develop, manufacture and commercialize product candidates or experience significant delays in doing so, our business may be harmed
35% rewrittenRisks Related to Our Business and Industry
We face substantial competition in a rapidly changing industry, which may result in others discovering, developing or commercializing products before or more successfully than we do
Was: We face substantial competition in rapidly changing industries, which may result in others discovering, developing or commercializing products before or more successfully than we do
35% rewrittenRisks Related to Our Business and Industry
Any litigation or adversarial proceedings could be costly and time-consuming to defend
33% rewrittenRisks Related to Ownership of Our Common Stock
Future acquisitions, strategic investments, partnerships or alliances could be difficult to identify and integrate, divert the attention of management, disrupt our business, dilute stockholder value and adversely affect our operating results and financial condition
29% rewrittenRisks Related to Ownership of Our Common Stock
The market price of our common stock has been, and may continue to be, volatile, which could result in substantial losses for investors
27% rewrittenRisks Related to Our Business and Industry
Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data
25% rewrittenRisks Relating to Our Intellectual Property
We may not be able to protect our intellectual property rights throughout the world
24% rewrittenRisks Related to Our Business and Industry
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
24% rewrittenRisks Related to Manufacturing
The manufacturing of cell therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates
Was: The manufacturing of cellular therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates
23% rewrittenRisks Related to Regulation and Legal Compliance
International expansion of our business would expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States
22% rewrittenRisks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital
We are a late-stage clinical cell therapy company that has incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future
Was: We are a clinical-stage biopharmaceutical company that has incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future

All 57 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital

01We are a late-stage clinical cell therapy company that has incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future22% rewritten
02We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts51% rewritten
03We currently have no products approved for sale and have never generated revenue from product sales. We may never generate revenue from product sales or achieve profitability
04We operate in a rapidly evolving field and have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability80% rewritten
05Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited82% rewritten
06We have long-lived assets, which are assessed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. In addition, we may never realize the full value of our long‑lived assets, causing us to record material impairment charges

Risks Related to Our Business and Industry

07If we are unable to successfully develop, manufacture and commercialize product candidates or experience significant delays in doing so, our business may be harmed39% rewritten
08and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to use and expand our technologies to develop any product candidateNew
09Clinical development involves a lengthy and expensive process with an uncertain outcome
10Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data27% rewritten
11We acquired ImmPACT in October 2024 and LYL273 in November 2025 and may not realize the benefits of such acquisitions or any potential future collaborations, licenses, product acquisitions or other strategic transactions58% rewritten
12We face substantial competition in a rapidly changing industry, which may result in others discovering, developing or commercializing products before or more successfully than we do35% rewritten
13We are highly dependent on our key personnel and, if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
14We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success24% rewritten
15We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us45% rewritten
16under our arrangements may be adversely affected by business combinations or significant changes in our collaborator’s business strategyNew
17Any litigation or adversarial proceedings could be costly and time-consuming to defend35% rewritten
18International trade policies, including tariffs, sanctions and trade barriers, may adversely affect our business, financial condition, results of operations and prospectsNew

Risks Related to Manufacturing

19The manufacturing of cell therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates24% rewritten
20Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all57% rewritten
21If our clinical manufacturing facility in Bothell, Washington or any of our potential contract manufacturing organizations is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affectedNew
22We may rely on third parties to manufacture our product candidates, which could subject us to risks and delay or prevent our development and/or commercialization, if approved, of our product candidates

Risks Related to Our Dependence on Third Parties

23Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites52% rewritten
24We have in the past, and we may in the future, form or seek collaborations or strategic alliances or enter into additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements49% rewritten
25In particular, failure by any collaborator to meet its obligations under our collaboration agreements or to apply sufficient efforts at developing and commercializing collaboration products may adversely affect our business, financial condition and our results of operationsNew

Risks Related to Regulation and Legal Compliance

26We are currently in clinical development of our product candidates, and our future success is dependent on the successful development and regulatory approval of our product candidates and any product candidates we acquire
27Our cell therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in our ability to achieve regulatory approval, commercialization or payor coverage of our product candidates67% rewritten
28The FDA and comparable foreign regulatory approval processes are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approvals of our product candidates, our business will be substantially harmed65% rewritten
29could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our productsNew
30Ronde-cel has received Fast Track and RMAT designations, and LYL273 has received Fast Track designation, from the FDA, but receipt of such designations or any other designation may not actually lead to a faster development, regulatory review or approval process, and does not assure ultimate FDA approval57% rewritten
31obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenueNew
32We may be subject to applicable fraud and abuse, including anti-kickback and false claims, transparency, health information privacy and security and other healthcare laws. Failure to comply with such laws may result in substantial penalties53% rewritten
33Changes in healthcare policies, laws and regulations may impact our ability to obtain approval for, or commercialize our product candidates, if approved95% rewritten
34International expansion of our business would expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States23% rewritten

Risks Relating to Our Intellectual Property

35If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected
36The lifespans of our patents may not be sufficient to effectively protect our products and business
37We may not be able to protect our intellectual property rights throughout the world25% rewritten
38We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties
39If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be adversely affected and our business could be harmed
40If we are sued for infringing the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our development and commercialization efforts
41We may face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third party’s trade secrets, we may be prevented from further using these trade secrets, which could limit our ability to develop our product candidates44% rewritten
42We have in-licensed a portion of our intellectual property from our partners and other third parties. If we breach any of our license agreements with these licensors, we could potentially lose the ability to continue the development and potential commercialization of one or more of our product candidates
43We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business
44We may be subject to claims challenging the inventorship of our patents and other intellectual property
45We may be subject to claims that our employees, consultants or independent contractors have breached non-compete or non-solicit obligations85% rewritten

Risks Related to Ownership of Our Common Stock

46The market price of our common stock has been, and may continue to be, volatile, which could result in substantial losses for investors29% rewritten
47Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or our products51% rewritten
48Future acquisitions, strategic investments, partnerships or alliances could be difficult to identify and integrate, divert the attention of management, disrupt our business, dilute stockholder value and adversely affect our operating results and financial condition33% rewritten
49Sales of a substantial number of shares of our common stock by our existing stockholders could cause the price of our common stock to decline50% rewritten
50If securities or industry analysts do not publish research or reports about our business, or if they publish negative or neutral evaluations of our stock, the price of our stock could decline
51The requirements of being a public company require our management to devote substantial time to compliance initiatives and corporate governance practices and could divert management’s attention and strain our resources64% rewritten
52Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
53Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock69% rewritten
54stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stockNew
55Changes in tax laws or regulations, including those that are applied adversely to us or our customers, may have a material adverse effect on our business, cash flow, financial condition, results of operations, effective tax rate or compliance costs41% rewritten
56Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price48% rewritten
57Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations

Other Lyell Immunopharma 10-Ks

FY2024 10-K risk factors
62 risks
Lyell is a clinical-stage biopharmaceutical company focused on T-cell therapies and the recently acquired IMPT-314 candidate. The company has incurred substantial net losses, has no approved products, and depends heavily on additional capital. Operations face risks from complex manufacturing processes, clinical trial execution, regulatory approvals, and intellectual property protection.
Filed Mar 11, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.